NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 200)
Posted On: 04/08/2022 3:28:46 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake – which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake – which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼